Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

2019-08-31
Price :
Published : Aug-2019
No. of Pages : 228

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Summary

Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care.

Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing antibodies, or inhibitors, against replacement factors. Overall, the late-stage pipeline indicates an increase in the development of alternative coagulation promoters (ACPs) and gene therapies to further target these areas of significant unmet need. During the forecast window, Roche entered the market with the first monoclonal antibody targeting hemophilia A patients both with and without inhibitors, which addresses the unmet needs of frequency and route of administration. Sanofi are also to exploring a non-replacement approach and will enter the market with the ribonucleic acid (RNA) therapeutic, Fitusiran (previously Alnylam’s), further ensuring cross-segment efficacy in patients both with and without inhibitors. The approval of these new products has begun to have a drastic effect on the hemophilia A and B treatment landscapes which is expected to continue through the forecast window. During this forecast window, several pharmaceutical companies, including BioMarin, uniQure and Pfizer/Roche (Spark Therapeutics), will also be launching new gene therapies that aim to cure, or at least reduce the severity of, hemophilia A and B and diminish inhibitors. If approved, gene therapies will pose a threat to existing hemophilia therapies.

GlobalData projects the global hemophilia A and B marketplace to experience a significant growth during the forecast period. GlobalData valued the hemophilia A and B market at $6.9B in 2018 in the 8MM and expects the market to increase to $9.3B in 2028 at a Compound Annual Growth Rate (CAGR) of 2.9%. This growth will be driven primarily by the increasing prophylactic treatment rates among patients, the continued use of recombinant products and the uptake of non-replacement therapies in the 8MM. However, cost constraints in the 8MM are expected to limit the premium pricing opportunities for new products such as late-to-market long-acting factor concentrates and new alternative coagulation promoters, thereby limiting the size of the hemophilia market.

This model covers the market forecast for marketed and late-stage pipeline hemophilia A and B therapeutics. The base year of this model is 2018, and the forecast period is 2018-2028.

Key Questions Answered

– Which pipeline agents – replacement factors, alternative coagulation promoters and gene therapies – are the most promising and expected to launch in the 8MM?
– What are the forecasted sales of these agents and what will be their impact in the hemophilia A and B market?
– What are the main unmet needs in hemophilia A and B, and which pipeline drugs will fulfil these needs, and to what extent?
– What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
– Key Opinions Leader (KOL) and payer insights across the 8MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Key Highlights

– The hemophilia A & B market is expected to grow at a CAGR of 2.9% until 2028, reaching a global value of $9.3B.
– GlobalData forecasts a marginal increase in prevalence rates across 8MM with AGR of 0.1% due to increased in prevalence rates across the US, Spain and UK.
– Gene therapies will emerge as novel treatments for hemophilia A & B during the forecast period. Particularly, BioMarin’s first-to-market gene therapy, ValRox is likely to perform exceptionally well. Additionally, Roche’s Hemlibra is anticipated to achieve blockbuster status by the end of the forecast period.
– Rising life expectancy for hemophilia patients leads to an increase in the size of the treated population.
– Expected launches of expensive new drugs such as gene therapies, continued preference for prophylactic regimens, continued patient evolution from plasma-based to recombinant therapies are other significant drivers of market.
– Limited scope for price premiums of late-to-market replacement products, high uptake of lower-priced drugs, rise in cost-consciousness and imposing market access barriers for the entry of expensive gene therapies are expected to affect market growth negatively.
– Level of unmet needs in hemophilia patients is high but is expected to decrease due to advances in treatments and the introduction of novel therapies.
– There are major market opportunities for the development of novel therapies, cheaper therapies for prophylaxis treatment, more effective treatments for hemophilia B patients with inhibitors and more therapies with convenient administration routes.

Scope

Overview of hemophilia A and B, including –
– Disease overview – etiology, pathophysiology, symptoms, prognosis and quality of life
– Epidemiology
– Disease management – diagnosis and treatment
Patient segmentation –
– Mild, Moderate, and Severe
– Hemophilia A and B with and without inhibitors
– Males and Females
– All ages, Pediatrics and Adults
Annualized hemophilia A and B therapeutics market revenue and treatment usage patterns –
– Patient shares and number of patients treated for marketed and pipeline products
– Duration of and, daily and annual cost of therapies per patient
– Product sales by usage and total sales of marketed and pipeline products

Key topics covered include –

– Competitive assessment of marketed and pipeline products including SWOTs and, clinical and commercial positioning.
– Unmet needs and opportunities including current and future level of attainment and gap analysis
– Pipeline assessment – analysis of commercial and clinical attributes of promising drugs in clinical development and comprehensive analysis of promising approaches and emerging trends in early stage development
– Analysis of the current and future players for the global hemophilia A and B market, including strength of marketed and pipeline products and trends in corporate strategy, profiles of leading companies in the hemophilia market.
– Market outlook of the 8MM including forecast, key events and, market drivers and barriers.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: In Vitro Diagnostic, Medical Device
Publisher : GlobalData
More Reports
Title Price Buy Now

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......
$7500

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......
$7500

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating ......
$7500

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......
$7500

Cytomegalovirus  (CMV) Tests (In Vitro Diagnostics) РGlobal Market Analysis and Forecast Model

"Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......
$7500

Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Prenatal Screening is now routinely used in developed countries for early detection of fetal abnormalities. Various biochemical analytes are measured during the first or second trimester including free-beta human chorionic gonadotropin (hCG), total hCG, pregnancy associated plasma protein-A (PAPP-A), Alpha-fetoprotein (AFP), unconjugated estriol (uE3), and Inhibin A. These markers are used to screen for Down syndrome (Trisomy 21) as well as Edwards syndrome (Trisomy 18) and ectopic pregnancy. Additionally, maternal s......
$7500

Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human T-Lymphotropic Virus (HTLV) is a retrovirus that infects T Lymphocyte cells. There are four strains of HTLV, out of these HTLV-I and HTLV-II are the most prevalent. HTLV-I is the causative agent of two severe neurological diseases. Specifically, sources indicate that up to 3-5% of patients infected with HTLV-I develop adult T-cell Leukemia/Lymphoma (ATLL) or HTLV-I-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Conversely, HTLV-II has been linked to elevate......
$7500

Hemostasis Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Hemostasis Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Hemostasis Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The increasing prevalence of surgical cases and rises in venous thromboembolism (VTE) incidence represent major driving factors for the hemostasis testing market. Prothrombin (PT) and Activated Prothrombin (aPTT) tests represent the most widely used Hemostasis tests. These devices are frequently utilized for coagulation testing prior to surgery while D-Dimer tests tend to be performed in VTE or suspected VTE cases. PT tests are also frequently used for monitoring of patients taking vitamin K antagonists such as warfarin......
$7500

Hematology Analyzers (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Hematology Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Hematology Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The market for automated Hematology Analyzers is increasing due to their reliability, advanced quality and fast testing mechanisms. The Hematology Analyzer market also benefits from rises in the prevalence of anaemia, increased incidence of blood related diseases and disorders, and the growing importance of blood cell counts in routine diagnostic procedures for patient treatment and monitoring. In developed and developing countries, hematology analyzers are installed in both hospital and reference laboratory set......
$7500

Colorectal Cancer Screening Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Colorectal Cancer Screening Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Colorectal Cancer Screening Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Aging populations and increasing disease awareness mean that colorectal cancer (CRC) screening has become a priority for many countries. A greater number of eligible inhabitants coupled with implementation of numerous national screening campaigns means that this in vitro diagnostics market is expected to grow across all regions during the forecast period. There are major disparities in the devices used for CRC screening around the world. Invasive colonoscopy procedures are the predomina......
$7500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy